BioCryst Pharmaceuticals, Inc.
8.115USD
-0.6900 (-7.84%)
Consensus EPS on the street’s adjusted basis, not the filed GAAP figure — which is why the actuals here can differ from the income statement.
| Period | Consensus EPS | 90 days ago | Revisions up (30d) | Revisions down (30d) |
|---|---|---|---|---|
| Current quarter | $0.12▲ | $0.11 | 2 | 0 |
| Next quarter | $0.13▲ | $0.08 | 2 | 0 |
| Current year | $0.75▲ | $0.57 | 1 | 1 |
| Next year | $0.94▲ | $0.68 | 0 | 2 |
Beat in 4 of the last 4
| Quarter | Estimate | Actual | Surprise |
|---|---|---|---|
| 2026-06-30 | $0.24 | $0.35 | +0.12 (+49.4%) |
| 2026-03-31 | $0.11 | $0.14 | +0.03 (+27.7%) |
| 2025-12-31 | $0.07 | $0.21 | +0.14 (+197.6%) |
| 2025-09-30 | $0.07 | $0.16 | +0.09 (+125.3%) |
138 ratings from 25 firms
Ratings are attributed to the research firm, not to individual analysts. See every ticker.
| Firm | Action | Rating | Price Target | Date |
|---|---|---|---|---|
| Needham | Reiterated | Buy | $16 | Sep 8, 2026 |
| RBC Capital | Maintained | Outperform | $14 $13 | Aug 6, 2026 |
| Wedbush | Maintained | Outperform | $21 $20 | Aug 6, 2026 |
| RBC Capital | Maintained | Outperform | $13 $14 | Jul 7, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $32 | Jun 30, 2026 |
| Cantor Fitzgerald | Maintained | Overweight | $27 $29 | Jun 30, 2026 |
| Citizens | Maintained | Market Outperform | $25 $28 | May 7, 2026 |
| Wedbush | Maintained | Outperform | $22 $21 | May 7, 2026 |
| Needham | Maintained | Buy | $18 $16 | May 6, 2026 |
| RBC Capital | Maintained | Outperform | $14 $13 | Jan 30, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $30 $32 | Dec 15, 2025 |
| Citizens | Maintained | Market Outperform | $27 $25 | Nov 5, 2025 |
| Barclays | Maintained | Equal-Weight | $11 $9 | Nov 4, 2025 |
| Needham | Maintained | Buy | $20 $18 | Nov 4, 2025 |
| Cantor Fitzgerald | Maintained | Overweight | $24 $26 | Oct 15, 2025 |
| JMP Securities | Maintained | Market Outperform | $17 $27 | Oct 15, 2025 |
| Needham | Maintained | Buy | $17 $20 | Oct 15, 2025 |
| Needham | Maintained | Buy | $17 | Aug 4, 2025 |
| B of A Securities | Maintained | Buy | $13 $15 | Jul 1, 2025 |
| RBC Capital | Reiterated | Outperform | $13 | Jun 30, 2025 |
| Wedbush | Maintained | Outperform | $16 $18 | Jun 30, 2025 |
| Needham | Reiterated | Buy | $17 | Jun 27, 2025 |
| Needham | Reiterated | Buy | $17 | Jun 25, 2025 |
| Barclays | Maintained | Equal-Weight | $8 $11 | May 7, 2025 |
| RBC Capital | Reiterated | Outperform | $11 $13 | May 6, 2025 |
73 filings from 16 insiders · 23 buy / 4 sell over 6m
Officers and directors of BCRX, from the last two years of filings. Grants, gifts and option exercises are shown but not colour-coded — they are compensation, not a view on the price.
| Insider | Action | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| MILNE JILL C. PH.D.Director | Grant | 1.3k | $9.70 | $12k | Aug 31, 2026 |
| FRANK STEVEN RDirector | Grant | 1.3k | $9.70 | $12k | Aug 31, 2026 |
| STONEHOUSE JON PDirector | Grant | 644 | $9.70 | $6k | Aug 31, 2026 |
| MCKEE AMY EDirector | Grant | 644 | $9.70 | $6k | Aug 31, 2026 |
| MILANO VINCENT JDirector | Grant | 1.2k | $9.70 | $11k | Aug 31, 2026 |
| MILNE JILL C. PH.D.Director | Grant | 15.3k | — | — | Jun 11, 2026 |
| FRANK STEVEN RDirector | Grant | 15.3k | — | — | Jun 11, 2026 |
| GALSON STEVEN KDirector | Grant | 15.3k | — | — | Jun 11, 2026 |
| STONEHOUSE JON PDirector | Grant | 15.3k | — | — | Jun 11, 2026 |
| MCKEE AMY EDirector | Grant | 15.3k | — | — | Jun 11, 2026 |
| HEGGIE THERESADirector | Grant | 15.3k | — | — | Jun 11, 2026 |
| SANDERS MACHELLEDirector | Grant | 15.3k | — | — | Jun 11, 2026 |
| LEVIN ALAN GDirector | Grant | 15.3k | — | — | Jun 11, 2026 |
| MILANO VINCENT JDirector | Grant | 15.3k | — | — | Jun 11, 2026 |
| MILNE JILL C. PH.D.Director | Grant | 1.3k | $8.91 | $11k | May 29, 2026 |
| FRANK STEVEN RDirector | Grant | 1.3k | $8.91 | $11k | May 29, 2026 |
| STONEHOUSE JON PDirector | Grant | 631 | $8.91 | $6k | May 29, 2026 |
| MCKEE AMY EDirector | Grant | 631 | $8.91 | $6k | May 29, 2026 |
| MILANO VINCENT JDirector | Grant | 1.1k | $8.91 | $10k | May 29, 2026 |
| MCKEE AMY EDirector | Sell | 11.2k | $8.97 | $100k | May 18, 2026 |
No analyst notes on BCRX yet.
Analyst Ratings
11 analysts covering
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Consensus |
|---|---|---|---|---|---|---|
| Current | 3 | 7 | 1 | 0 | 0 | Buy1.82 |
| 1 mo ago | 3 | 7 | 1 | 0 | 0 | Buy1.82 |
| 2 mo ago | 3 | 7 | 1 | 0 | 0 | Buy1.82 |
| 3 mo ago | 3 | 7 | 0 | 0 | 0 | Buy1.70 |